AMENDMENT TO THE CLAIMS:

The current listing of claims as follows will replace all previously entered claims. :

Listing of Claims

1. (Currently Amended) An ~~Fc variant~~ antibody and/or immunoadhesin of a parent Fc polypeptide, said ~~Fc variant~~ antibody and/or immunoadhesin comprising at least one amino acid modification in the Fc region of said parent Fc polypeptide said modification occurring at a position selected from the group consisting of: 228, 230, 231, 232, 240, 244, 245, 247, 262, 263, 266, 271, 273, 275, 281, 284, 291, 299, 302, 304, 313, 323, 325, 328, 332, and 336, wherein said ~~Fc variant~~ antibody and/or immunoadhesin protein exhibits altered binding to an FcγR as compared to the parent Fc polypeptide, wherein numbering is according to the EU index.

2. (Currently Amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 1, wherein said ~~Fc variant~~ antibody and/or immunoadhesin comprises at least one substitution selected from the group consisting of: 230, 240, 244, 245, 247, 262, 263, 266, 273, 275, 299, 302, 313, 323, 325, 328, and 332.

3. (Currently Amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 1, wherein said altered binding is an increase in affinity of said ~~Fc variant~~ antibody and/or immunoadhesin to said FcγR.

4. (Currently Amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 3, wherein said ~~Fc variant~~ antibody and/or immunoadhesin binds with greater affinity to a mouse FcγR.

5. (Currently Amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 3, wherein said said FcγR is a human Fc receptor selected from the group consisting of FcγRI, FcγRIIa, FcγRIIb, FcγRIIc, and FcγRIIIa.

6. (Currently Amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 3, wherein said ~~Fc variant~~ antibody and/or immunoadhesin binds with greater affinity to human FcγRI and FcγRIIIa, but exhibits unaltered affinity to a human receptor selected from the group consisting of FcγRIIa, FcγRIIb, and FcγRIIc.

7. (Currently Amended) ~~Fc variant~~ antibody and/or immunoadhesin according to claim 6, wherein said ~~Fc variant~~ antibody and/or immunoadhesin exhibits unaltered affinity to FcγRIIa, FcγRIIb, and FcγRIIc.

8. (Withdrawn – currently amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 3, wherein the affinity increase for binding to one or more human FcγRII's is greater than the affinity increase for binding to human FcγRI or FγRIIIa.

9. (Withdrawn – currently amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 3, wherein the affinity increase is the same for binding to FcγRIIa, FcγRIIb, and FcγRIIc.

10. (Withdrawn – currently amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 3, wherein the affinity increase for binding to FcγRIIc is greater than the affinity increase for binding to FcγRIIb.

11. (Withdrawn) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 3, wherein said ~~Fc variant~~ antibody and/or immunoadhesin binds with greater affinity to human FcγRIIa, but exhibits unaltered affinity to a human receptor selected from the group consisting of FcγRI, FcγRIIb, FcγRIIc, and FcγRIIIa.

12. (Withdrawn – currently amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 11, wherein said ~~Fc variant~~ antibody and/or immunoadhesin exhibits unaltered affinity to FcγRI, FcγRIIb, FcγRIIc, and FcγRIIIa.

13. (Currently Amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to any of claims ~~1-12~~ 1-7, wherein said ~~Fc variant~~ antibody and/or immunoadhesin binds with greater affinity to FcRn.

14. (Withdrawn – currently amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to any of claims 1-12, wherein said ~~Fc variant~~ antibody and/or immunoadhesin binds with unaltered affinity to FcRn.

15. (Withdrawn – currently amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to any of claims 1-12, wherein said ~~Fc variant~~ antibody and/or immunoadhesin binds with reduced affinity to FcRn.

16. (Withdrawn – currently amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to any of claims 1-12, wherein said ~~Fc variant~~ antibody and/or immunoadhesin binds with greater affinity to C1q or enhances complement dependent cytotoxicity (CDC).

17. (Currently Amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to any of claims ~~1-12~~ 1-7, wherein said ~~Fc variant~~ antibody and/or immunoadhesin binds with unaltered affinity to C1q or enhances CDC.

18. (Withdrawn – currently amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 1, wherein said ~~Fc variant~~ antibody and/or immunoadhesin further comprises an engineered glycoform.

19. (Withdrawn – currently amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 18 wherein said engineered glycoform comprises an altered level of fucosylation or bisecting oligosaccharides as compared to the parent Fc polypeptide.

20. (Withdrawn) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 18 wherein said engineered glycoform improves effector function.

21. (Currently Amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 1, wherein said ~~Fc variant~~ antibody and/or immunoadhesin enhances or reduces an effector function selected from the group consisting of antibody dependent cell-mediated cytotoxicity (ADCC), CDC, or antibody dependent cell-mediated phagocytosis (ADCP) function as compared to the parent Fc polypeptide.

22. (Currently Amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 21, wherein said effector function is antibody dependent cell-mediated cytotoxicity (ADCC).

23. (Currently Amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 22, wherein said ~~Fc variant~~ antibody and/or immunoadhesin improves ADCC in the presence of human effector cells as compared to said parent Fc polypeptide.

24. (Currently Amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 22, wherein said ADCC improvement is an enhancement in potency such that the EC50 of said ~~Fc variant~~ antibody and/or immunoadhesin is approximately 5-fold greater than that of said parent Fc polypeptide.

25. (Currently Amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 23, wherein said ADCC improvement is an enhancement in potency such that the EC50 of said ~~Fc variant~~ antibody and/or immunoadhesin is between approximately 5-fold and 1000-fold greater than that of said parent Fc polypeptide.

26. (Currently Amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 23, wherein said ADCC improvement is an enhancement in efficacy such that the maximal ADCC is approximately 2-fold greater than that of said parent Fc polypeptide.

27. (Currently Amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 26, wherein said ~~Fc variant~~ antibody and/or immunoadhesin improves ADCC in the presence of mouse effector cells as compared to said parent Fc polypeptide.

28. (Currently Amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 21, wherein said effector function is ADCP.

29. (Currently Amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 28, wherein said ~~Fc variant~~ antibody and/or immunoadhesin improves ADCP as compared to said parent Fc polypeptide.

30. (Currently Amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 25 or 29, wherein CDC is unaffected.

31. (Currently Amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 25 or 29, wherein CDC is ablated.

32. (Currently Amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 1 wherein said polypeptide has specificity for a target antigen selected from the group consisting of CD4, CD19, CD20, CD22, CD25, CD30, CD33, CD52, CD80, B7-1, B7-2, CLTA-4, BAFF-R, Her2/neu, EGFR, EpCAM, MUC1, GD3, CEA, CA 125, HLA-DR, TNFalpha, and VEGF.

33. (Currently Amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 1 or 21 comprising a modification selected from the group consisting of 228E, 228K, 228Y, 228G, 230E, 230Y, 230G, 231E, 231K, 231Y, 231P, 231G, 232E, 232K, 232Y, 232G, 262E, 262F, 271D, 271E, 271N, 271Q, 271K, 271R, 271S, 271T, 271H, 271A, 271V, 271L, 271I, 271F, 271M, 271Y, 271W, 271G, 275L, 281D, 281K, 281Y, 281P, 284E, 284N, 284T, 284L, 284Y, 291D, 291E, 291Q, 291T, 291H, 291I, 291G, 299D, 299E, 299N, 299Q, 299K, 299R,

299L, 299F, 299M, 299Y, 299W, 299P, 299G, 304D, 304N, 304T, 304H, 304L, 325K, 325R, 325S, 325F, 325M, 325Y, 325W, 325P, 325G, 328D, 328Q, 328K, 328R, 328S, 328T, 328V, 328I, 328Y, 328W, 328P, 328G, 332K, 332R, 332S, 332V, 332L, 332F, 332M, 332W, 332P, 332G, 336E, 336K, 336Y, 230A, 240A, 240I, 240M, 240T, 244H, 245A, 247G, 247V, 262A, 262E, 262I, 262T, 263A, 263I, 263M, 263T, 266A, 266I, 266M, 266T, 273I, 275W, 299A, 299E, 299F, 299H, 299I, 299L, 299S, 299V, 302I, 313F, 323I, 325A, 325D, 325E, 325H, 325I, 325L, 325Q, 325T, 325V, 328A, 328D, 328E, 328F, 328H, 328I, 328M, 328N, 328Q, 328T, 328V, 332A, 332D, 332E, 332H, 332N, 332Q, 332T, and 332Y.

34. (Currently Amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 1 wherein said parent Fc polypeptide is an antibody comprising said ~~Fc variant~~ antibody and/or immunoadhesin.

35. (Currently Amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 1 wherein said ~~Fc variant~~ antibody and/or immunoadhesin is an Fc fusion protein comprising said ~~Fc variant~~ antibody and/or immunoadhesin.

36. (Currently Amended) A pharmaceutical composition comprising an ~~Fc variant~~ antibody and/or immunoadhesin according to claim 1 and a pharmaceutically acceptable carrier.

37. (Withdrawn – currently amended) A method of treating a mammal in need of said treatment, comprising administering a ~~variant~~ antibody and/or immunoadhesin protein of claim 1.

38. (Withdrawn – currently amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claims 1or 33 comprising at least one modification selected from the group consisting of A330L/I332E, D265F/N297E/I332E, D265Y/N297D/I332E, D265Y/N297D/T299L/I332E, F241E/F243Q/V262T/V264E, F241E/F243Q/V262T/V264E/I332E, F241E/F243R/V262E/V264R, F241E/F243R/V262E/V264R/I332E, F241E/F243Y/V262T/V264R, F241E/F243Y/V262T/V264R/I332E, F241L/F243L/V262I/V264I, F241L/V262I, F241R/F243Q/V262T/V264R, F241R/F243Q/V262T/V264R/I332E, F241W/F243W/V262A/V264A, F241Y/F243Y/V262T/V264T, F241Y/F243Y/V262T/V264T/N297D/I332E, F243L/V262I/V264W, F243L/V264I, L328D/I332E, L328E/I332E, L328H/I332E, L328I/I332E, L328M/I332E, L328N/I332E, L328Q/I332E, L328T/I332E, L328V/I332E, N297D/A330Y/I332E, N297D/I332E, N297D/I332E/S239D/A330L, N297D/S298A/A330Y/I332E, N297D/T299E/I332E, N297D/T299F/I332E, N297D/T299H/I332E, N297D/T299I/I332E, N297D/T299L/I332E, N297D/T299V/I332E, N297E/I332E, N297S/I332E, P230A/E233D/I332E, P244H/P245A/P247V, S239D/A330L/I332E, S239D/A330Y/I332E, S239D/A330Y/I332E/K326E, S239D/A330Y/I332E/K326T, S239D/A330Y/I332E/L234I, S239D/A330Y/I332E/L235D, S239D/A330Y/I332E/V240I, S239D/A330Y/I332E/V264T, S239D/A330Y/I332E/V266I, S239D/D265F/N297D/I332E, S239D/D265H/N297D/I332E, S239D/D265I/N297D/I332E, S239D/D265L/N297D/I332E, S239D/D265T/N297D/I332E, S239D/D265V/N297D/I332E, S239D/D265Y/N297D/I332E, S239D/I332D, S239D/I332E, S239D/I332E/A330I, S239D/I332N, S239D/I332Q, S239D/N297D/I332E, S239D/N297D/I332E/A330Y, S239D/N297D/I332E/A330Y/F241S/F243H/V262T/V264T, S239D/N297D/I332E/K326E, S239D/N297D/I332E/L235D, S239D/S298A/I332E, S239D/V264I/A330L/I332E, S239D/V264I/I332E, S239D/V264I/S298A/I332E, S239E/D265N, S239E/D265Q, S239E/I332D, S239E/I332E, S239E/I332N, S239E/I332Q, S239E/N297D/I332E, S239E/V264I/A330Y/I332E, S239E/V264I/I332E, S239E/V264I/S298A/A330Y/I332E, S239N/A330L/I332E, S239N/A330Y/I332E, S239N/I332D, S239N/I332E, S239N/I332N, S239N/I332Q, S239N/S298A/I332E, S239Q/I332D, S239Q/I332E, S239Q/I332N, S239Q/I332Q, S239Q/V264I/I332E, S298A/I332E,

V264E/N297D/I332E, V264I/A330L/I332E, V264I/A330Y/I332E,V264I/I332E, V264I/S298A/I332E, Y296D/N297D/I332E, Y296E/N297D/I332E, Y296H/N297D/I332E, Y296N/N297D/I332E, Y296Q/N297D/I332E, and Y296T/N297D/I332E.

39. (Withdrawn – currently amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claims 1, 33 or 38 further comprising a modification selected from the group consisting of 227E, 227K, 227Y, 227G, 233N, 233Q, 233K, 233R, 233S, 233T, 233H, 233A, 233V, 233L, 233I, 233F, 233M, 233Y, 233W, 233G, 234K, 234R, 234S, 234A, 234M, 234W, 234P, 234G, 235E, 235K, 235R, 235A, 235M, 235W, 235P, 235G, 236D, 236E, 236N, 236Q, 236K, 236R, 236S, 236T, 236H, 236A, 236V, 236L, 236I, 236F, 236M, 236Y, 236W, 236P, 237D, 237E, 237N, 237Q, 237K, 237R, 237S, 237T, 237H, 237V, 237L, 237I, 237F, 237M, 237Y, 237W, 237P, 238D, 238E, 238N, 238Q, 238K, 238R, 238S, 238T, 238H, 238V, 238L, 238I, 238F, 238M, 238Y, 238W, 238G, 239Q, 239K, 239R, 239V, 239L, 239I, 239M, 239W, 239P, 239G, 241D, 241E, 241Y, 243E, 246D, 246E, 246H, 246Y, 249Q, 249H, 249Y, 255E, 255Y, 258S, 258H, 258Y, 260D, 260E, 260H, 260Y, 264D, 264E, 264N, 264Q, 264K, 264R, 264S, 264H, 264W, 264P, 264G, 265Q, 265K, 265R, 265S, 265T, 265H, 265V, 265L, 265I, 265F, 265M, 265Y, 265W, 265P, 267E, 267Q, 267K, 267R, 267V, 267L, 267I, 267F, 267M, 267Y, 267W, 267P, 268D, 268E, 268Q, 268K, 268R, 268T, 268V, 268L, 268I, 268F, 268M, 268W, 268P, 268G, 269K, 269S, 269V, 269I, 269M, 269W, 269P, 269G, 270R, 270S, 270L, 270I, 270F, 270M, 270Y, 270W, 270P, 270G, 272D, 272R, 272T, 272H, 272V, 272L, 272F, 272M, 272W, 272P, 272G, 274D, 274N, 274S, 274H, 274V, 274I, 274F, 274M, 274W, 274P, 274G, 276D, 276T, 276H, 276V, 276I, 276F, 276M, 276W, 276P, 276G, 278D, 278N, 278Q, 278R, 278S, 278H, 278V, 278L, 278I, 278M, 278P, 278G, 280K, 280L, 280W, 280P, 280G, 282E, 282K, 282Y, 282P, 282G, 283K, 283H, 283L, 283Y, 283P, 283G, 285D, 285E, 285Q, 285K, 285Y, 285W, 286E, 286Y, 286P, 286G, 288D, 288E, 288Y, 290D, 290N, 290H, 290L, 290W, 292D, 292E, 292T, 292Y, 293N, 293R, 293S, 293T, 293H, 293V, 293L, 293I, 293F, 293M, 293Y, 293W, 293P, 293G, 294K, 294R, 294S, 294T, 294H, 294V, 294L, 294I, 294F, 294M, 294Y, 294W, 294P, 294G, 295D, 295E, 295N, 295R, 295S, 295T, 295H, 295V, 295I, 295F, 295M, 295Y, 295W, 295P, 295G, 296K, 296R, 296A, 296V, 296M, 296G, 297Q, 297K, 297R, 297T, 297H, 297V, 297L, 297I, 297F, 297M, 297Y, 297W, 297P, 297G, 298D. 298E,

298Q, 298K, 298R, 298I, 298F, 298M, 298Y, 298W, 300D, 300E, 300N, 300Q, 300K, 300R, 300S, 300T, 300H, 300A, 300V, 300M, 300W, 300P, 300G, 301D, 301E, 301H, 301Y, 303D, 303E, 303Y, 305E, 305T, 305Y, 317E, 317Q, 318Q, 318H, 318L, 318Y, 320N, 320S, 320H, 320V, 320L, 320F, 320Y, 320W, 320P, 320G, 322D, 322S, 322V, 322I, 322F, 322Y, 322W, 322P, 322G, 324H, 324F, 324M, 324W, 324P, 324G, 326P, 327E, 327K, 327R, 327H, 327V, 327I, 327F, 327M, 327Y, 327W, 327P, 329D, 329E, 329N, 329Q, 329K, 329R, 329S, 329T, 329H, 329V, 329L, 329I, 329M, 329Y, 329W, 329G, 330E, 330N, 330T, 330P, 330G, 331D, 331Q, 331R, 331T, 331L, 331I, 331F, 331M, 331Y, 331W, 333L, 333F, 333M, 333P, 334P, 335N, 335S, 335H, 335V, 335L, 335I, 335F, 335M, 335W, 335P, 335G, 337E, 337N, 337H, 233D, 234D, 234E, 234F, 234H, 234I, 234N, 234Q, 234T, 234V, 234Y, 235D, 235F, 235H, 235I, 235N, 235Q, 235S, 235T, 235V, 235Y, 239D, 239E, 239F, 239H, 239N, 239Q, 239T, 239Y, 241E, 241L, 241R, 241S, 241W, 241Y, 243H, 243L, 243Q, 243R, 243W, 243Y, 264A, 264E, 264F, 264I, 264L, 264M, 264R, 264T, 264W, 264Y, 265F, 265G, 265H, 265I, 265L, 265N, 265Q, 265T, 265V, 265Y, 267D, 267H, 267L, 267N, 267Q, 267T, 269F, 269H, 269L, 269N, 269R, 269T, 269Y, 270H, 270Q, 270T, 272I, 272K, 272S, 272Y, 274E, 274L, 274R, 274T, 274Y, 276E, 276L, 276R, 276S, 276Y, 278E, 278K, 278T, 278W, 283R, 296D, 296E, 296H, 296I, 296L, 296N, 296Q, 296S, 296T, 297D, 297E, 297S, 298A, 298H, 298N, 298T, 318R, 320D, 320I, 320T, 322H, 322T, 324D, 324I, 324L, 324R, 324T, 324V, 324Y, 326E, 326I, 326L, 326T, 327D, 327L, 327N, 327S, 327T, 329F, 330F, 330H, 330I, 330L, 330M, 330R, 330S, 330V, 330W, 330Y, 331H, 331V, 333A, 333H, 333I, 333T, 333Y, 334A, 334F, 334I, 334T, 335D, 335R, and 335Y.

40. (Withdrawn – currently amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 1 wherein said ~~Fc variant~~ antibody and/or immunoadhesin further comprises a set of modifications selected from 241W/243W, 267Q/327S, 243L/264I, 234I/235D, 264E/297D/332E, 239E/265N, 239E/265Q, 239E/265G, 267L/327S and 240I/266I.

41. (Withdrawn – currently amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 33 wherein said antibody is a full length antibody.

42. (Withdrawn – currently amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 33 wherein said antibody is a human antibody.

43. (Withdrawn – currently amended) An ~~Fc variant~~ antibody and/or immunoadhesin according to claim 33 wherein said antibody is an antibody fragment.

44-45. (Canceled)